Gene Therapy for Parkinson’s Disease is under clinical development by Innervate Therapeutics and currently in Phase II for Parkinson’s Disease. According to GlobalData, Phase II drugs for Parkinson’s Disease have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gene Therapy for Parkinson’s Disease’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy for Parkinson’s Disease overview
The therapeutic candidate is under development for the treatment of Parkinson’s disease. It comprises of adeno associated virus 5 (AAV5) vector delivering glial cell-derived neurotrophic factor (GDNF). It is administered through parenteral route. It is being developed based on Convection Enhanced Delivery (CED) technology.
Innervate Therapeutics overview
Innervate Therapeutics operates in the pharmaceuticals and healthcare industry, specializing in the central nervous system therapy area. It focuses on developing treatments for disorders related to the central nervous system. The company is headquartered in South Glamorgan, Wales, the UK.
For a complete picture of Gene Therapy for Parkinson’s Disease’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
